The UK government has signed a new deal with vaccine creators GSK and Sanofi for some trail drugs which are considered to be effective.
Tho they already have a signed agreement of 100 million doses of the Oxford University vaccine being developed by AstraZeneca they further signed this new deal to check which can work faster.
However, it’s still uncertain which, if any, of the vaccines may work.
The vaccine involved within the newest government deal, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology employed by Sanofi to provide a flu vaccine, also as GSK’s established pandemic technology.
Sanofi, which is leading the clinical development, said regulatory approval could be achieved by the first half of 2021 if trials were successful.
In the meantime, Sanofi and GSK are scaling up manufacturing to provide up to a minimum of one billion doses a year overall.
The vaccine has already been at the center of a world political storm after Sanofi rowed back on a transparent promise to prioritize the US market.
Sanofi chief executive Paul Hudson sparked a row in May by saying the US government had “the right to the foremost important pre-order because it’s invested in taking the risk”.
“With our partner GSK, we are pleased to co-operate with the UK government also as several other countries and global organizations as a neighborhood of our ongoing efforts to develop a secure and effective vaccine and make it available as quickly as possible,” said Thomas Triomphe, executive vice-president and global head of Sanofi Pasteur.
Roger Connor, president of GSK Vaccines, added: “We thank the UK government for confirmation of shopping for intent, which supports the various investment we are already making as an organization to proportion development and production of this vaccine.”
Kate Bingham, who chairs the UK government’s Vaccines Taskforce, said: “This diversity of vaccine types is significant because we do not yet know which, if any, of the varied kinds of the vaccine will convince generate a secure and protective response to Covid-19.
“Whilst this agreement is extremely good news, we mustn’t be complacent or over-optimistic.”